Gut microbiota diversity repeatedly diminishes over time following maintenance infliximab infusions in paediatric IBD patients.

<h4>Background</h4>The gut microbiome plays a crucial role in the pathogenesis and progression of inflammatory bowel disease (IBD). Understanding the dynamics of the gut microbiome in relation to treatment can provide valuable insights into disease management and therapy strategies. The...

Full description

Saved in:
Bibliographic Details
Main Authors: Katrine Carlsen, Louise B Thingholm, Astrid Dempfle, Mikkel Malham, Corinna Bang, Andre Franke, Vibeke Wewer
Format: Article
Language:English
Published: Public Library of Science (PLoS) 2024-01-01
Series:PLoS ONE
Online Access:https://doi.org/10.1371/journal.pone.0311604
Tags: Add Tag
No Tags, Be the first to tag this record!
_version_ 1846119309597736960
author Katrine Carlsen
Louise B Thingholm
Astrid Dempfle
Mikkel Malham
Corinna Bang
Andre Franke
Vibeke Wewer
author_facet Katrine Carlsen
Louise B Thingholm
Astrid Dempfle
Mikkel Malham
Corinna Bang
Andre Franke
Vibeke Wewer
author_sort Katrine Carlsen
collection DOAJ
description <h4>Background</h4>The gut microbiome plays a crucial role in the pathogenesis and progression of inflammatory bowel disease (IBD). Understanding the dynamics of the gut microbiome in relation to treatment can provide valuable insights into disease management and therapy strategies. The aim of this study is to investigate if diversity and composition of the gut microbiome correlate with time since treatment and disease activity during maintenance infliximab (IFX) therapy among children with IBD.<h4>Methods</h4>Data was collected from IBD patients aged 10-17 participating in an IFX-eHealth study. IFX infusions were administered in 4-12-week intervals based on weekly faecal calprotectin (FC) combined with symptom scores. Excess stool samples underwent microbiome profiling using 16S rRNA gene sequencing. Microbiome features, including alpha diversity and single taxa, were analysed for three key variables: 1) weeks-since-treatment, 2) FC, and 3) symptom score.<h4>Results</h4>From 25 patients (median age 14.4 years) diagnosed with Crohn´s Disease (n = 16) or ulcerative colitis (n = 9), microbiota were analysed in 671 faecal samples collected across 15 treatment intervals. A significant decrease over time in Shannon diversity, following the initial increase within four weeks of treatment, was found across patients. FC levels showed no association with alpha diversity (p>0.1), while symptom scores showed a negative association with Shannon and observed diversity in patients with UC. At the genus level, a lower abundance of the genera Anaerostipes and Fusicatenibacter (Firmicutes), and a greater abundance of the genus Parasutterella (Proteobacteria), were associated (p.adj<0.05) with the time elapsed since last infusion in UC specifically, while only Parasutterella was associated across the full cohort (p.adj = 1e-10).<h4>Conclusions</h4>We found a recurring reduction over time in alpha diversity following the initial increase in diversity after an IFX infusion. Changes in an individual's microbiome may be an early sign of increasing disease activity that precedes clinical symptoms and increased FC.
format Article
id doaj-art-253d60f18b2d4761b2332d18c419ddc0
institution Kabale University
issn 1932-6203
language English
publishDate 2024-01-01
publisher Public Library of Science (PLoS)
record_format Article
series PLoS ONE
spelling doaj-art-253d60f18b2d4761b2332d18c419ddc02024-12-17T05:31:47ZengPublic Library of Science (PLoS)PLoS ONE1932-62032024-01-011912e031160410.1371/journal.pone.0311604Gut microbiota diversity repeatedly diminishes over time following maintenance infliximab infusions in paediatric IBD patients.Katrine CarlsenLouise B ThingholmAstrid DempfleMikkel MalhamCorinna BangAndre FrankeVibeke Wewer<h4>Background</h4>The gut microbiome plays a crucial role in the pathogenesis and progression of inflammatory bowel disease (IBD). Understanding the dynamics of the gut microbiome in relation to treatment can provide valuable insights into disease management and therapy strategies. The aim of this study is to investigate if diversity and composition of the gut microbiome correlate with time since treatment and disease activity during maintenance infliximab (IFX) therapy among children with IBD.<h4>Methods</h4>Data was collected from IBD patients aged 10-17 participating in an IFX-eHealth study. IFX infusions were administered in 4-12-week intervals based on weekly faecal calprotectin (FC) combined with symptom scores. Excess stool samples underwent microbiome profiling using 16S rRNA gene sequencing. Microbiome features, including alpha diversity and single taxa, were analysed for three key variables: 1) weeks-since-treatment, 2) FC, and 3) symptom score.<h4>Results</h4>From 25 patients (median age 14.4 years) diagnosed with Crohn´s Disease (n = 16) or ulcerative colitis (n = 9), microbiota were analysed in 671 faecal samples collected across 15 treatment intervals. A significant decrease over time in Shannon diversity, following the initial increase within four weeks of treatment, was found across patients. FC levels showed no association with alpha diversity (p>0.1), while symptom scores showed a negative association with Shannon and observed diversity in patients with UC. At the genus level, a lower abundance of the genera Anaerostipes and Fusicatenibacter (Firmicutes), and a greater abundance of the genus Parasutterella (Proteobacteria), were associated (p.adj<0.05) with the time elapsed since last infusion in UC specifically, while only Parasutterella was associated across the full cohort (p.adj = 1e-10).<h4>Conclusions</h4>We found a recurring reduction over time in alpha diversity following the initial increase in diversity after an IFX infusion. Changes in an individual's microbiome may be an early sign of increasing disease activity that precedes clinical symptoms and increased FC.https://doi.org/10.1371/journal.pone.0311604
spellingShingle Katrine Carlsen
Louise B Thingholm
Astrid Dempfle
Mikkel Malham
Corinna Bang
Andre Franke
Vibeke Wewer
Gut microbiota diversity repeatedly diminishes over time following maintenance infliximab infusions in paediatric IBD patients.
PLoS ONE
title Gut microbiota diversity repeatedly diminishes over time following maintenance infliximab infusions in paediatric IBD patients.
title_full Gut microbiota diversity repeatedly diminishes over time following maintenance infliximab infusions in paediatric IBD patients.
title_fullStr Gut microbiota diversity repeatedly diminishes over time following maintenance infliximab infusions in paediatric IBD patients.
title_full_unstemmed Gut microbiota diversity repeatedly diminishes over time following maintenance infliximab infusions in paediatric IBD patients.
title_short Gut microbiota diversity repeatedly diminishes over time following maintenance infliximab infusions in paediatric IBD patients.
title_sort gut microbiota diversity repeatedly diminishes over time following maintenance infliximab infusions in paediatric ibd patients
url https://doi.org/10.1371/journal.pone.0311604
work_keys_str_mv AT katrinecarlsen gutmicrobiotadiversityrepeatedlydiminishesovertimefollowingmaintenanceinfliximabinfusionsinpaediatricibdpatients
AT louisebthingholm gutmicrobiotadiversityrepeatedlydiminishesovertimefollowingmaintenanceinfliximabinfusionsinpaediatricibdpatients
AT astriddempfle gutmicrobiotadiversityrepeatedlydiminishesovertimefollowingmaintenanceinfliximabinfusionsinpaediatricibdpatients
AT mikkelmalham gutmicrobiotadiversityrepeatedlydiminishesovertimefollowingmaintenanceinfliximabinfusionsinpaediatricibdpatients
AT corinnabang gutmicrobiotadiversityrepeatedlydiminishesovertimefollowingmaintenanceinfliximabinfusionsinpaediatricibdpatients
AT andrefranke gutmicrobiotadiversityrepeatedlydiminishesovertimefollowingmaintenanceinfliximabinfusionsinpaediatricibdpatients
AT vibekewewer gutmicrobiotadiversityrepeatedlydiminishesovertimefollowingmaintenanceinfliximabinfusionsinpaediatricibdpatients